Sanofi Tries Again With Cytokines, Inking R&D Alliance With Startup Synthekine
Sanofi and Synthekine will work together to develop cytokine therapies for inflammatory diseases. This new alliance comes as Sanofi is salvaging a different cytokine therapy that showed disappointing efficacy in Phase 2 after the pharma giant acquired it in a $2.5 billion deal.
John Bertin Nektar Therapeutics Bristol Myers Squibb Menlo Park California Based Synthekine Bristol Myers
Source: medcitynews.com